Skip to main content
Canna~Fangled Abstracts

UK Medical Cannabis Registry analyzes pain outcomes

By March 13, 2025No Comments

 

PubMed is a free, comprehensive database of scientific and medical literature, primarily focusing on biomedical and life sciences research. It is maintained by the National Library of Medicine (NLM) at the National Institutes of Health (NIH). PubMed is one of the most widely used resources for healthcare professionals, researchers, and students to access peer-reviewed articles, clinical studies, and other scientific publications.

. 2025 Mar;7(3):e70024.

doi: 10.1002/acr2.70024.

UK Medical Cannabis Registry: An Analysis of Outcomes of Medical Cannabis Therapy for Hypermobility-Associated Chronic Pain

Mary Dickinson 1, Simon Erridge 2, John Warner-Levy 1, Evonne Clarke 3, Katy McLachlan 3, Ross Coomber 4, Wendy Holden 3, James J Rucker 5, Michael W Platt 3, Mikael H Sodergren 2
Affiliations 

Abstract

Objective: The study aims to evaluate the clinical outcomes in patients with hypermobility spectrum disorder (HSD) and hypermobile Ehlers-Danlos syndrome (hEDS) with chronic pain following treatment with cannabis-based medicinal products (CBMPs).

Methods: This was a case series conducted with the UK Medical Cannabis Registry. The primary outcomes were changes in the following validated patient-reported outcome measures at 1, 3, 6, 12, and 18 months compared with baseline: Short-Form McGill Pain Questionnaire 2 (SF-MPQ-2), pain visual analog scale score (Pain-VAS), Brief Pain Inventory (BPI), five-level EQ-5D (EQ-5D-5L), Single-Item Sleep Quality Scale (SQS), General Anxiety Disorder Seven-Item Scale (GAD-7), and Patient Global Impression of Change. The incidence of adverse events was analyzed as secondary outcomes. Statistical significance was defined as P <0.050.

Results: A total of 161 patients met inclusion criteria. Improvements were observed in BPI severity and interference subscales, SF-MPQ-2, and Pain-VAS (P < 0.001). Changes were also seen in the EQ-5D-5L index value, SQS, and GAD-7 (P < 0.001). A total of 50 patients (31.06%) reported one or more adverse event with a total incidence of 601 (373.29%). The most frequent rating for adverse events was moderate (n = 258; 160.25%), with headache being the most common (n = 44; 27.33%).

Conclusion: An association was identified between patients with HSD/hEDS with chronic pain and improvements in pain-specific and general health-related quality of life following the commencement of CBMPs. CBMPs were also well tolerated at 18 months. These findings must be interpreted within the context of the limitations of study design but add further weight to calls for randomized controlled trials.

PubMed Disclaimer

References

REFERENCES

    1. Atwell K, Michael W, Dubey J, et al. Diagnosis and management of hypermobility spectrum disorders in primary care. J Am Board Fam Med 2021;34:838–848.
    1. Castori M, Tinkle B, Levy H, et al. A framework for the classification of joint hypermobility and related conditions. Am J Med Genet C Semin Med Genet 2017;175:148–157.
    1. Gensemer C, Burks R, Kautz S, et al. Hypermobile Ehlers‐Danlos syndromes: complex phenotypes, challenging diagnoses, and poorly understood causes. Dev Dyn 2021;250:318–344.
    1. Tinkle BT, Bird HA, Grahame R, et al. The lack of clinical distinction between the hypermobility type of Ehlers–Danlos syndrome and the joint hypermobility syndrome (a.k.a. hypermobility syndrome). Am J Med Genet A 2009;149:2368–2370.
    1. Kumar B, Lenert P. Joint hypermobility syndrome: recognizing a commonly overlooked cause of chronic pain. Am J Med 2017;130:640–647.

 

Stay informed with the latest scientific insights, evidence-based independent research and discoveries on the ECS, cannabis medicine and more

Revolutionary Research on the ECS, cannabinoids and cannabis-based medicine for healthcare from a trusted nonprofit.

Leave a Reply